Imperial Brands PLC
8
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
88%
7 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
A Relative Bioavailability Study of Nicotine Delivery From Selected Oral Nicotine Products
Role: lead
A Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product
Role: lead
Nicotine Pharmacokinetic Study of Heated Tobacco and Heated Herbal Products
Role: lead
A Randomised, Cross-Over, Nicotine Pharmacokinetic and Pharmacodynamic Study of Heated Tobacco Products Compared to Combustible Cigarettes
Role: lead
A Randomised, Cross-over, Relative Bioavailability Study of Nicotine Delivery and Nicotine Extraction From Oral Products
Role: lead
An Exploratory PET-study of Deposition, Disposition and Brain Uptake of [11C]Nicotine After Inhalation of 2 Nicotine Formulations Via the myBluTM E-cigarette in Smokers
Role: lead
A Nicotine Pharmacokinetics and Smoking Behaviour Study Examining Cigarette Ingredients
Role: collaborator
A Study to Evaluate the Safety Profile of an e-Vapour Product
Role: lead
All 8 trials loaded